Impact of pharmacotherapy on the incidence of transurethral prostatectomy for benign prostatic hyperplasia and the implications for surgical training.
AffiliationMercy University Hospital, Grenville Place, Cork. email@example.com
MeSH5-alpha Reductase Inhibitors/therapeutic use
Adrenergic alpha-1 Receptor Antagonists/therapeutic use
Prostatic Hyperplasia/*drug therapy/surgery
Transurethral Resection of Prostate/*trends/utilization
MetadataShow full item record
CitationIr Med J. 2010 Oct;103(9):281-2.
JournalIrish medical journal
AbstractMedical therapy has become first line treatment for Benign Prostatic Hypertrophy (BPH) and in many cases TURP may no longer be required. Proof and quantification of this evolution in practice has been somewhat elusive and provided the principle impetus for this study. This is a retrospective study of BPH management in Republic of Ireland from 1995 to 2008. National treatment databases were sourced for numbers undergoing TURP and pharmacotherapy prescribing data was obtained from individual pharmaceutical companies. A total of 28,240 TURP's were performed nationally between 1995 and 2008. TURP's performed annually, decreased by 1,494 (51%), alpha-blocker prescriptions increased from 8,710 to 302,159 units and the number of urology trainees increased by 10 (60%). Clear association between decreases in TURP's and increases in pharmacotherapy for BPH is demonstrated. Implications on training likely exist and will require proper evaluation in order to maintain future standards in this surgical practice.
- Impact of medical therapy on transurethral resection of the prostate: two decades of change.
- Authors: Izard J, Nickel JC
- Issue date: 2011 Jul
- Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
- Authors: Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G
- Issue date: 2014 Feb
- The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
- Authors: Agha AH, Roy JB, Culkin DJ, Lyon K
- Issue date: 1995 Nov-Dec
- Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
- Authors: Liatsikos E, Kyriazis I, Kallidonis P, Stolzenburg JU
- Issue date: 2011 Sep
- Alpha blocker prazosin for the treatment of benign prostatic hypertrophy (BPH).
- Authors: Punekar SV, Kelkar AR, Gavande PM, Rao NR, Date JA, Prem AR
- Issue date: 1995 Oct-Dec